TGF-β secreted by malignant epithelial cells, CAFs, and immunocytes further generate an immune-suppressive niche via metabolic reprogramming of the tumor and by orchestrating the inactivation of immune cells, leading to a decrease in the efficacy of anti-cancer immunotherapies [33]. This evidence concerns the gene TGFB1 and cancer.